Pharma BD Deal Intelligence

Boston Scientific Corporation / BTG plc

2018 · Acquisition/Merger · $4.2B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Boston Scientific acquired BTG plc for approximately $4.2 billion in cash. The acquisition expanded Boston Scientific's interventional medicine portfolio, particularly in interventional oncology and vascular therapies.

Key facts

Announced Nov 20, 2018
Closed Aug 19, 2019
Deal value $4.2B
Deal type Acquisition/Merger
Therapeutic area Oncology
Key assets TheraSphere (interventional oncology), EKOS endovascular system, Varithena

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals